High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C (Part 2)
Consensus IFN (CIFN) is a genetically engineered molecule derived by aligning the sequences of all known alpha IFN s and assigning the most commonly observed amino acid in each sequence. Studies have shown that treatment of naive subjects with HCV infection with 9 |ag CIFN gives a sustained virological response similar to that of standard IFN alpha-2b, but the former is more effective in those with a high viral load and/or with genotype 1 infection (15 |ag CIFN is equivalent to 3.75 MIU IFN alpha-2b). Retreatment with CIFN for 12 months has been shown to be effective in achieving a sustained response of 58% in relapsers to previous IFN alpha-2b or CIFN given for six months and 13% in nonresponders to six months of prior IFN monotherapy when given for 12 months.
The purpose of the present study was to evaluate the efficacy of high dose CIFN (15 |ag daily) induction therapy given for 12 weeks followed by CIFN (15 |ag) three times per week for a further 3 6 weeks in patients with chronic HCV infection who were nonresponders to previous therapy with a complete course of IFN alpha-2b and ribavirin (ie, those who had received greater than 80% of the recommended IFN alpha-2b and greater than 80% of the recommended dose of ribavirin for their body weight for 80% of the recommended duration of therapy). It was hypothesized that CIFN given in a daily dose would be able to achieve a greater antiviral effect by achieving higher serum concentrations, allowing for less chance of viral breakthrough and development of viral resistance during therapy. Get most advantageous deals offered to you by the pharmacy you are going to appreciate soon after you become its customer: you now can get your *cialis professional online any time of the day or night with very fast delivery and quality guarantees.